CAR T-cell therapy is generally considered for patients with certain types of blood cancers who have not responded to conventional treatments or have relapsed after other therapies.
It is often recommended for individuals who are not suitable candidates for stem cell transplants or who have exhausted other treatment options. Eligibility is assessed based on the type and stage of cancer, previous treatment responses, and overall health condition.
Indications for CAR T-cell therapy generally include:
- Relapsed or Refractory Blood Cancers: Patients with certain types of blood cancers, such as acute lymphoblastic leukemia (ALL), diffuse large B-cell lymphoma (DLBCL), and other B-cell lymphomas, who have not responded to initial treatments or have relapsed.
- Inadequate Response to Standard Treatments: Patients whose cancer has not responded adequately to conventional therapies like chemotherapy, radiation, or targeted drugs.
- Ineligibility for Stem Cell Transplant: Patients who are not suitable candidates for stem cell transplants or who have experienced relapse after a transplant.
- Specific Cancer Markers: Patients with cancers that express specific antigens targeted by CAR T-cell therapy, such as CD19 in many current CAR T-cell products.
Eligibility and specific indications can vary based on ongoing research, product approvals, and individual patient factors.
